Arcturus Therapeutics Holdings Inc
$ 8.85
0.11%
17 Apr - close price
- Market Cap 251,260,000 USD
- Current Price $ 8.85
- High / Low $ 9.19 / 8.83
- Stock P/E N/A
- Book Value 7.53
- EPS -2.46
- Next Earning Report 2026-05-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.16 %
- ROE -0.29 %
- 52 Week High 24.17
- 52 Week Low 5.85
About
Arcturus Therapeutics Holdings Inc., an RNA drug company, focuses on the treatment of liver and respiratory diseases. The company is headquartered in San Diego, California.
Analyst Target Price
$23.30
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-02 | 2025-11-10 | 2025-08-04 | 2025-06-13 | 2025-03-05 | 2024-11-07 | 2024-08-05 | 2024-05-08 | 2024-03-07 | 2023-11-14 | 2023-08-07 | 2023-05-09 |
| Reported EPS | -1.03 | -0.49 | -0.34 | -0.52 | -1.11 | -0.26 | -0.64 | -1 | -0.32 | -0.61 | -1.98 | 1.87 |
| Estimated EPS | 4.28 | 5.53 | 3.21 | -1.19 | -0.4943 | -1.22 | -1.6 | -1.19 | -0.99 | -1.69 | -0.21 | 0.06 |
| Surprise | -5.31 | -6.02 | -3.55 | 0.67 | -0.6157 | 0.96 | 0.96 | 0.19 | 0.67 | 1.08 | -1.77 | 1.81 |
| Surprise Percentage | -124.0654% | -108.8608% | -110.5919% | 56.3025% | -124.56% | 78.6885% | 60% | 15.9664% | 67.6768% | 63.9053% | -842.8571% | 3016.6667% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-11 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -1.14 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ARCT
2026-04-15 21:39:50
This article analyzes Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) using AI models, identifying strong near and mid-term sentiment with a weak long-term outlook. It highlights a significant 248.0:1 risk-reward setup, targeting a 69.0% gain. The piece also outlines three distinct institutional trading strategies for different risk profiles: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy.
2026-04-15 00:40:27
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has received a consensus "Moderate Buy" rating from thirteen brokerages, with an average 12-month price target of $29.50. Despite recent mixed results including a missed earnings estimate and some price target cuts, other firms have initiated coverage with buy ratings, contributing to the overall positive outlook. Institutional investors hold approximately 94.54% of the company's shares.
2026-04-06 08:41:51
HC Wainwright & Co. has downgraded Arcturus Therapeutics Holdings (ARCT) stock. This indicates a revised, more cautious outlook from the financial firm regarding the company's future performance. Investors and market watchers should note this change in analyst sentiment.
2026-04-06 06:39:34
HC Wainwright & Co. has downgraded its rating for Arcturus Therapeutics Holdings (ARCT). This downgrade indicates a less optimistic outlook from the financial firm regarding the company's stock performance. Investors will likely monitor ARCT's future developments and financial reports following this analyst action.
2026-04-04 20:16:00
This article provides an in-depth analysis of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT), highlighting strong near and mid-term sentiment but a weak long-term outlook. It details three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with specific entry, target, and stop-loss zones. The analysis also covers multi-timeframe signal strengths, support, and resistance levels for ARCT.
2026-04-02 09:39:40
Hennion & Walsh Asset Management Inc. significantly increased its stake in Arcturus Therapeutics Holdings Inc. by purchasing an additional 161,910 shares, bringing its total ownership to 240,303 shares valued at approximately $1.47 million. Despite some analysts lowering price targets, Arcturus Therapeutics maintains a "Moderate Buy" consensus rating with an average target of $29.50. The biotechnology company, trading at around $7.85, recently reported a Q4 earnings miss with ($1.03) EPS and $7.2M in revenue, while institutional investors hold a substantial 94.54% of its shares.
